Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...
Ropes & Gray, Morrison & Foerster and Big Four Japanese firm Mori Hamada are advising Bain Capital on the $3.3 billion acquisition of Mitsubishi Tanabe Pharma Corporation (MTPC). MTPC, which is ...
Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.
The investment is being led by Bain Capital’s Private Equity teams in Asia and North America together with the firm’s Life Sciences team and values the business at approximately 510 billion JPY (3.3 ...
Bain Capital is in the final stages of negotiations to acquire Mitsubishi Chemical Group’s pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback